AALBERTS NV 39.300 € (-0,41 %)
BNP PARIBAS ACT.A 100.700 € (+0,88 %)
ASML HOLDING 1 569.000 € (-2,11 %)
LVMH 489.900 € (-0,62 %)
INVENTIVA 3.730 € (0,00 %)
SANOFI 76.230 € (-0,33 %)
SCOR SE 31.880 € (+1,01 %)
PHILIPS KON 24.060 € (+0,59 %)
SCHNEIDER ELECTRIC 269.650 € (-0,13 %)
AVANTIUM 7.090 € (+0,28 %)
ARCADIS 34.520 € (+0,88 %)
CARREFOUR 16.490 € (+0,95 %)
AIRBUS 197.260 € (+0,38 %)
PERNOD RICARD 64.200 € (+0,94 %)
VINCI 119.000 € (-0,29 %)
POUJOULAT 5.400 € (+0,37 %)
CELLECTIS 2.590 € (-4,15 %)
STMICROELECTRONICS 62.000 € (-1,08 %)
FORVIA 9.082 € (+0,89 %)
SMCP 5.170 € (-0,19 %)
2CRSI 30.700 € (-3,46 %)
S.E.B. 46.640 € (-0,04 %)
NANOBIOTIX 35.560 € (+4,28 %)
ASM INTERNATIONAL 910.400 € (-1,77 %)
PLANISWARE 20.550 € (+0,24 %)
MAUREL ET PROM 7.785 € (-1,64 %)
NEXITY 7.575 € (0,00 %)
SOITEC 98.000 € (-5,86 %)
THALES 223.300 € (-1,54 %)
DBV TECHNOLOGIES 2.852 € (+0,07 %)
CREDIT AGRICOLE 17.490 € (+0,37 %)
SARTORIUS STED BIO 183.300 € (+2,06 %)
MEXEDIA 3.630 € (-5,84 %)
VOLTALIA 6.900 € (-2,13 %)
CAPGEMINI 88.960 € (-0,04 %)
MEDINCELL 27.100 € (-2,66 %)
SES 7.705 € (-1,03 %)
INPOST 15.470 € (+0,32 %)
MAGNUM 16.308 € (+2,40 %)
COMPAGNIE ODET 1 456.000 € (-0,41 %)
ING GROEP N.V. 28.415 € (-0,05 %)
DANONE 72.420 € (0,00 %)
AIR LIQUIDE 174.300 € (+0,77 %)
ORANGE 15.870 € (+0,03 %)
GREEN EARTH GROUP 1.180 € (+3,06 %)
LAKEFRONT BIOTHER. 26.320 € (-1,20 %)
BENETEAU 6.070 € (-0,49 %)
STREAMWIDE 71.000 € (-6,58 %)
GETLINK SE 18.480 € (-0,65 %)
NEXANS 134.000 € (+0,90 %)
HEIJMANS KON 100.100 € (-4,03 %)
KERLINK 1.165 € (-3,72 %)
HIPAY GROUP 5.460 € (-2,15 %)
CORBION 20.520 € (-0,39 %)
CA TOULOUSE 31 CCI 128.000 € (-4,32 %)
NRJ GROUP 6.840 € (-0,58 %)
CRCAM NORM.SEINE 162.500 € (-0,61 %)
NACON 0.206 € (-2,83 %)
FUGRO 9.675 € (+0,52 %)
TOMTOM 4.600 € (-0,22 %) |
24/04/2023 07:00
Evolva publishes timeline of the Reverse Stock SplitEvolva Holding SA / Key word(s): AGMEGM
Reinach, 24 April 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, today communicates on the timeline of the reverse stock split of 250:1 which was approved by shareholders at the Annual General Meeting on 18 April 2023 by a large majority:
The reverse split of shares may result in fractions of new registered shares for the individual shareholder. This is the case if shareholders hold an amount of Evolva shares that is not divisible by 250 or a multiple thereof after the 25 April 2023. Fractions in new shares are rounded down to the next whole number and shareholders will receive an equivalent cash compensation for their fractions. Further information regarding the reverse split can be found in the Q&A on Evolva's website (Link).
Important dates 24 August 2023 Half-year 2023 results
Contact Doris Rudischhauser Head of Investor Relations and Corporate Communications +41 79 410 81 88
About Evolva Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to wellness, health and sustainability. Find out more at evolva.com and connect with us on LinkedIn. For Evolva multimedia content, please visit: evolva.com/multimedia-library.
Disclaimer
End of Media Release
1614491 24.04.2023 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière